Senores Pharmaceuticals gets nod to acquire 100% share capital of Apnar Pharma

16 Dec 2025 Evaluate

Senores Pharmaceuticals has received approval for the acquisition of 100% share capital of Apnar Pharma. In this regard, the company has entered into a Share Purchase Agreement (SPA) with Apnar Pharma, is a pharmaceutical company primarily engaged in the business of manufacture of generic pharmaceutical formulations, having US FDA, UK-MHRA and Health Canada approved manufacturing facility near Vadodara, Gujarat.

The said transaction is to be completed in two tranches, first tranche of the transaction to be completed in current fiscal by March 2026 and second tranche is expected to complete by Q2 of FY 2027. Upon consummation of the acquisition shall become a wholly owned subsidiary of the company. The Management Committee of the Board of Directors of the company, in its meeting held on December 15, 2025, has considered and approved the same.

Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.

Senores Pharmaceutic Share Price

820.15 4.60 (0.56%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×